Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Impact on Skin Resident Memory T Cells
NCT03983460Unknown
- Sponsor
- Association pour la Recherche Clinique et Immunologique
- Start
- Mar 2020
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of dupilumab + topical corticosteroids in atopic dermatitis (AD) (2 arms), sponsored by Association pour la Recherche Clinique et Immunologique. Primary endpoint: Change of the number and/or frequency of immune cells in skin and blood at Day 168. Status: unknown.
02
Drugs
dupilumab + topical corticosteroids
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03983460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983460.